A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on Cyp3a4

Epilepsia

Volumn 48, Issue 3, 2007, Pages 490-496

  Andreasen, Astrid Helene ^a   Brøsen, Kim ^a   Damkier, Per ^b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Carbamazepine; CYP3A4; Drug drug interaction; Oxcarbazepine; P450 induction

Indexed keywords

3 HYDROXYQUINIDINE; BIOLOGICAL MARKER; CARBAMAZEPINE; CYTOCHROME P450 3A4; OXCARBAZEPINE; QUINIDINE SULFATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; FATIGUE; HUMAN; LABORATORY TEST; MALE; MENTAL CONCENTRATION; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; ANTICONVULSANTS; AREA UNDER CURVE; BIOLOGICAL MARKERS; CARBAMAZEPINE; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; HUMANS; MALE; QUINIDINE;

EID: 33847690754     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2007.00924.x     Document Type: Article

References (30)

1. Baruzzi A, Albani F, Riva R. (1994) Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 35:S14-S19.
2. Bertilsson L, Tomson T, Tybring G. (1986) Pharmacokinetics: time-dependent changes - autoinduction of carbamazepine epoxidation. Journal of Clinical Pharmacology 26:459-462.
3. Brosen K, Davidsen F, Gram LF. (1990) Quinidine kinetics after a single oral dose in realtion to the sparteine oxidation polymorphism in man. British Journal of Clinical Pharmacology 29:248-253.
4. Brosen K, Kragh-Sorensen P. (1993) Concomitant intake of nortriptylin and carbamazepine. A case report. Therapeutic Drug Monitoring 15:259-260.
5. Damkier P, Brosen K. (2000) Quinidine as a probe for CYP3A4 activity: Intrasubject variability and a lack of correlation with probe-based assays for CYP1A2, CYP2C19, and CYP2D6. Clinical Pharmacology and Therapeutics 68:199-209.
6. Doose DR, Wang SS, Padmanabhan M, Schwarbe S, Jacobs D, Bialer M. (2003) Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethidrone and ethinyl estradiol in healthy obese and nonobese female subject. Epilepsia 55:540-549.
7. Fattore C, Cipolla G, Gatti G, Limido GL, Sturm Y, Bernasconi C, Perucca E. (1999) Induction of ethinylestraiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 40:783-787.
8. Flesch G, Tudor D, D'Souza J, Hossain M. (2002) Oxcarbazepine final market image tablet formulation bioequivalence study after single administration and at steady state in healthy subjects. International Journal of Clinical Pharmacology and Therapeutics 40:524-532.
9. Giessmann T, May K, Modess C, Wegner D, Hecker U, Zschiesche H, Grube M, Schroeder E, Warzok R, Cascorbi I, Kroemer H, Siegmund W. (2004) Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clinical Pharmacology and Therapeutics 76:192-200.
10. Houtkooper MA, Lammertsma A, Meyer JWA, Goedhart DM, Meinardi H, van Oorschot CA, Blom GF, Hoppener RJ, Hulsman JA. (1987) Oxcarbazepine (GP 47.680): A possible alternative to carbamazepine? Epilepsia 28:693-698.
11. Klosterskov-Jensen P, Saano V, Haring P, Svenstrup B, Menge GP. (1992) Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia 33:1149-1152.
12. Larkin JG, McKee PJW, Forrest G, Beastall GH, Park BK, Lowrie JI, Lloyd P, Brodie MJ. (1991) Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. British Journal of Cinical Pharmacology 31:65-71.
13. Lucas RA, Gilfillan DJ, Bergstrom RF. (1998) A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. European Journal of Clinical Pharmacology 54:639-643.
14. Mecarelli O, Vicenzini E, Pulitano P, Vanacore N, Romolo FS, Di Piero V, Lenzi GL, Accornero N. (2004) Clinical, cognitive, and neurophysiologic correlates of shortterm treatment with carbamazepine, oxcarbazepine, and levetiracetam in healthy volunteers. The Annals of Pharmacotherapy 38:1816-1822.
15. Miceli JJ, Anziano RJ, Robarge L, Hansen RA, Laurent A. (2000) The effect of carbamazepine on the steady-state pharmakokinetics of ziprasidone in healthy volunteers. British Journal of Cinical Pharmacology 49:65S-70S.
16. Nielsen F, Kramer Nielsen K, Brosen K. (1994) Determination of quinidine, dihydroquinidine, (3S)-3-hydroxyquinidine and quinidine Noxide i plasma and urine by high-performance liquid chromatography. Journal of Chromatography B 660:103-110.
17. Nielsen TL, Rasmussen BR, Flinois JP, Beaune P, Brosen K. (1999) In vitro mechanism of quinidine: The (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytorchrome p-4503A4 activity in human liver microsomes. The Journal of Pharmacology and Experimental Therapeutics 289:31-37.
18. Owen A, Pirmohamed M, Tettey JN, Morgan P, Chadwick D, Kevin Park B. (2001) Carbamazepine is not a substrate for P-glycoprotein. British Journal of Cinical Pharmacology 51:345-349.
19. Patasalos PN, Perucca E. (2003) Clinically important interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurology 2:347-356.
20. Patsalos PN, Zakrzewska JM, Elyas AA. (1990) Dose dependent enzyme induction by oxcarbazepine? European Journal of Pharmacology 39:187-188.
21. Pihlsg̊ard M, Eliasson E. (2002) Significant reduction of sertraline plasma levels by carbamazepine and phenytoin. European Journal of Clinical Pharmacology 57:915-916.
22. R̈osche J, Fr̈oscher W, Abendroth D, Liebel J. (2001) Possible oxcarbazepine interaction with cyclosporine serum levels: a single case study. Clinical Neuropharmacology 24:113-116.
23. Sitsen JMA, Maris FA, Timmer CJ. (2001) Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects. European Journal of Drug Metabolism and Pharmacokinetics 26:109-121.
24. Spina E, Pisani F, Perucca E. (1996) Clinically significant pharmacokinetic interactions with carbamazepine. Clinical Pharmacokinetics 31:198-214.
25. Stahl SM. (2004) Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels. The Journal of Cinical Psychiatry 65:738-739.
26. Szymura-Oleksiak J, Wyska E, Wasieczko A. (2001) Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. Psycopharmacology 154:38-42.
27. Thummel KE, Wilkinson GR. (1998) In vitro and in vivo drug interactions involving human CYP3A. Annual Review of Pharmacology and Toxicology 38:389-430.
28. Ucar M, Neuvonen M, Luurila H, Dahlqvist R, Neuvonen PJ, Mj̈orndal T. (2004) Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. European Journal of Clinical Pharmacology 59:879-882.
29. Volosov A, Xiaodong S, Perucca E, Yagen B, Sintov A, Bialer M. (1999) Enantioselective pharmacokinetics of 10-hydroxycarbazine after oral administration of oxcarbazepine to healthy Chinese subjects. Clinical Pharmacology and Therapeutics 66:547-553.
30. Zaccara G, Gangemi PF, Bendoni L, Menge GP, Schwarbe S, Monza GC. (1993) Influence of a single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine. Therapeutic Drug Monitoring 15:39-42.